Whether you like or don't like the College Football Playoff's decision to expand its field to 12 teams, the argument that it would destroy the importance of the regular season hasn't held up. And ...

So, a year after reaching the SEC title game, Texas is a pretender? What else are we to think after the Longhorns offense sputtered again at Florida? This week's SEC Power Rankings weren't kind to ...

In general, I’m not a big collector of the sort of things people tend to collect—baseball cards, shot glasses, stamps, wine, bobble heads, records, etc. But about 10 years ago, I had the thought when ...

Analyse the historical data and BI Matrix Co Ltd share price performance charts on this page. Our technical summary section provides analysis on BI Matrix share price buy/sell indicators using ...

Follow ZDNET: Add us as a preferred source on Google. I've spent large portions of my life looking for ways to extend the battery life on my Android phones. Admittedly, that sounds rather dramatic, ...

You eat with your eyes first. It's why Michelin Star restaurants spend so much time on meticulous presentation that half the diners probably don't even notice. It's why the waiter tantalizingly ...

If the National Peoples’ Power (NPP) party learns just three lessons as it passes the one year high water mark in holding the reins of power, it would do well to be a little more self-critical, a tad ...

Diwali 2025: Fairylights are one of the top picks for illuminating homes this festival of lights. They are widely used not only because they are easily available, but also because they instantly ...

Compound interest grows by reinvesting earnings, creating larger interest over time. Increasing compounding frequency (e.g., monthly) can significantly accelerate investment growth. Compound earnings ...

Assam Chief Minister Himanta Biswa Sarma, on October 12, launched the Chief Minister's Foreign Language Initiative (CM-FLIGHT), a program to train 50,000 state youth in the Japanese language and ...

The FDA today unveiled a plan to accelerate development of biosimilars in hopes of significantly reducing drug costs in the United States.